BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...By Jeff Cranmer, Executive Editor Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230...
...trials, said Chairman, President and CEO Charlie McDermott.TARGETSTLR7 – Toll-like receptor 7 Jeff Cranmer Elucida Oncology AbbVie Dragonfly Therapeutics Primmune Therapeutics Bioqube Tessera...
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

...insertions with high efficiency has been much more difficult, and that’s one of the places Tessera’s...
...paste, or cut and write curative sequences,” said CEO, co-founder and director Geoffrey von Maltzahn. Tessera’s...
...specific indications, but von Maltzahn said genetic diseases make sense as early targets. He said Tessera...
BioCentury | Jul 15, 2017
Company News

Management tracks

...named Paul Stockdale CFO, effective September 15. He succeeds Katie Long, who is returning to Tessera...
BioCentury | Apr 23, 2007
Company News

Onconome, Proteome Sciences deal

...characterize Onconome’s antibodies for diagnostic and prognostic tests for prostate and colon cancers. Onconome (formerly Tessera Inc....
BioCentury | Apr 4, 2005
Company News

Tessera sales and marketing update

...ProstaMark EPCA analyte specific reagent (ASR) for use in detecting prostate cancer in biopsy tissue. Tessera Inc....
BioCentury | Aug 2, 2004
Company News

GTx, Tessera Inc deal

...incidence of prostate cancer in men with PIN. The samples will be used to evaluate Tessera's...
...to identify patients with PIN lesions and/or early-stage prostate cancer. GTx Inc. (GTXI), Memphis, Tenn. Tessera...
BioCentury | Nov 12, 2001
Company News

Applied Gene Technologies Inc., AsiaGen deal

...Applied Gene will develop tuberculosis (TB) diagnostics using its Tessera array technology. Applied Gene will receive...
BioCentury | Jun 25, 2001
Clinical News

Tessera array technology regulatory update

...probe for rapid nucleic acid sample processing. Applied Gene Technologies Inc., San Diego, Calif. Product: Tessera...
BioCentury | Mar 5, 2001
Clinical News

Tessera Array Technology regulatory update

...Applied Gene received U.S. Patent No. 6,187,566 covering its Tessera Array Technology, which labels nucleic acid...
...samples to infectious disease- and cancer-related probes. Applied Gene Technologies Inc., San Diego, Calif. Product: Tessera...
Items per page:
1 - 9 of 9
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...By Jeff Cranmer, Executive Editor Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230...
...trials, said Chairman, President and CEO Charlie McDermott.TARGETSTLR7 – Toll-like receptor 7 Jeff Cranmer Elucida Oncology AbbVie Dragonfly Therapeutics Primmune Therapeutics Bioqube Tessera...
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

...insertions with high efficiency has been much more difficult, and that’s one of the places Tessera’s...
...paste, or cut and write curative sequences,” said CEO, co-founder and director Geoffrey von Maltzahn. Tessera’s...
...specific indications, but von Maltzahn said genetic diseases make sense as early targets. He said Tessera...
BioCentury | Jul 15, 2017
Company News

Management tracks

...named Paul Stockdale CFO, effective September 15. He succeeds Katie Long, who is returning to Tessera...
BioCentury | Apr 23, 2007
Company News

Onconome, Proteome Sciences deal

...characterize Onconome’s antibodies for diagnostic and prognostic tests for prostate and colon cancers. Onconome (formerly Tessera Inc....
BioCentury | Apr 4, 2005
Company News

Tessera sales and marketing update

...ProstaMark EPCA analyte specific reagent (ASR) for use in detecting prostate cancer in biopsy tissue. Tessera Inc....
BioCentury | Aug 2, 2004
Company News

GTx, Tessera Inc deal

...incidence of prostate cancer in men with PIN. The samples will be used to evaluate Tessera's...
...to identify patients with PIN lesions and/or early-stage prostate cancer. GTx Inc. (GTXI), Memphis, Tenn. Tessera...
BioCentury | Nov 12, 2001
Company News

Applied Gene Technologies Inc., AsiaGen deal

...Applied Gene will develop tuberculosis (TB) diagnostics using its Tessera array technology. Applied Gene will receive...
BioCentury | Jun 25, 2001
Clinical News

Tessera array technology regulatory update

...probe for rapid nucleic acid sample processing. Applied Gene Technologies Inc., San Diego, Calif. Product: Tessera...
BioCentury | Mar 5, 2001
Clinical News

Tessera Array Technology regulatory update

...Applied Gene received U.S. Patent No. 6,187,566 covering its Tessera Array Technology, which labels nucleic acid...
...samples to infectious disease- and cancer-related probes. Applied Gene Technologies Inc., San Diego, Calif. Product: Tessera...
Items per page:
1 - 9 of 9